Tag Archive for: Clinical Trial

Alys Pharmaceuticals doses first subject in Phase 1/1b trial of ALY-301, a first-in-class mast cell selective c-Kit inhibitor for Chronic Urticaria

/in

Differentiated profile of ALY-301 designed to enable chronic dosing in mast cell dependent diseases while avoiding the safety limitations of conventional c-Kit inhibitors Multicenter Phase 1/1b study to enroll both healthy volunteers and patients with Cold Urticaria with initial data readouts expected in 2026 Boston, Massachusetts and Lausanne, Switzerland, 30 October 2025 – Alys Pharmaceuticals, […]

Read more

Data from GNT-018-IDES trial supports feasibility of imlifidase as pretreatment in gene therapy treatment for patients with Crigler–Najjar syndrome who are immune to AAV

/in

Results presented today at ESGCT 2025 PARIS, France, LUND, Sweden (October 10, 2025) – Genethon, a worldwide pioneer and leader in research and development of gene therapy for rare genetic diseases, and Hansa Biopharma, a Sweden-based leader in IgG cleaving enzyme technology announced today that a patient with a rare liver disease and immunity to the AAV […]

Read more

Heidelberg Pharma Advances to Cohort 9 in Phase I/IIa Trial of Lead ATAC Candidate HDP-101 in Multiple Myeloma

/in

HDP-101 continues to demonstrate a favorable safety profile with no dose-limiting toxicities observed Early evidence of clinical activity observed in Cohort 8, highlighted by a very good partial response observed in one patient Ladenburg, Germany, 25 September 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today […]

Read more

Resolution Therapeutics appoints Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer

/in

Highly experienced Chief Financial Officer set to drive corporate and strategic goals of Resolution. Accomplished Chief Business Officer will drive business development and partnering deals. Appointments follow the announcement of the first patient dosed and safety cleared in its Phase I/II EMERALD study. Edinburgh and London, UK 10 September 2025 – Resolution Therapeutics (“Resolution” or “Company”), a clinical-stage biopharmaceutical […]

Read more

DeuterOncology to Present Promising Phase I DO-2 MET Kinase Inhibitor Data at WCLC 2025

/in

DO-2 is a best-in-class MET kinase inhibitor that has completed enrollment in a Phase 1 dose escalation study Tumor shrinkage was observed in 100% of MET exon 14 skip NSCLC patients without additional oncogenic drivers, at doses that achieved preclinically defined thresholds DO-2 has a very good safety profile with minimal peripheral oedema and clean […]

Read more